$5.13
Monopar Therapeutics is a biotechnology business based in the US. Monopar Therapeutics shares (MNPR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.15 – an increase of 1.38% over the previous week. Monopar Therapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.
What's in this guide?
Our top picks for where to buy Monopar Therapeutics stock
- Earn 4.5% interest on uninvested cash with Gold
- Get up to $50,000 in instant deposits with Gold
- Easy, user-friendly trading
- Unlimited bonus amounts Oct 16-27
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Monopar Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – MNPR. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Monopar Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Monopar Therapeutics stock price (NASDAQ: MNPR)
Use our graph to track the performance of MNPR stocks over time.Monopar Therapeutics shares at a glance
Latest market close | $5.15 |
---|---|
52-week range | $1.37 - $8.65 |
50-day moving average | $3.65 |
200-day moving average | $3.37 |
Wall St. target price | $18.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-2.30 |
Is it a good time to buy Monopar Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Monopar Therapeutics price performance over time
Historical closes compared with the close of $5.39 from 2024-10-14
1 week (2024-10-09) | 6.10% |
---|---|
1 month (2024-09-16) | 28.64% |
3 months (2024-07-16) | 629.36% |
6 months (2024-04-16) | 640.38% |
1 year (2023-10-16) | 1,046.81% |
---|---|
2 years (2022-10-14) | 199.44% |
3 years (2021-10-15) | 9.78% |
5 years (2019-10-12) | N/A |
Monopar Therapeutics financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -53.45% |
Return on equity TTM | -102.31% |
Profit margin | 0% |
Book value | $1.73 |
Market Capitalization | $18.1 million |
TTM: trailing 12 months
Monopar Therapeutics share dividends
We're not expecting Monopar Therapeutics to pay a dividend over the next 12 months.
Have Monopar Therapeutics's shares ever split?
Monopar Therapeutics's shares were split on a 1:5 basis on 12 August 2024. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Monopar Therapeutics shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Monopar Therapeutics shares which in turn could have impacted Monopar Therapeutics's share price.
Monopar Therapeutics share price volatility
Over the last 12 months, Monopar Therapeutics's shares have ranged in value from as little as $1.37 up to $8.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Monopar Therapeutics's is 1.261. This would suggest that Monopar Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Monopar Therapeutics overview
Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Frequently asked questions
What percentage of Monopar Therapeutics is owned by insiders or institutions?Currently 53.327% of Monopar Therapeutics shares are held by insiders and 2.315% by institutions. How many people work for Monopar Therapeutics?
Latest data suggests 9 work at Monopar Therapeutics. When does the fiscal year end for Monopar Therapeutics?
Monopar Therapeutics's fiscal year ends in December. Where is Monopar Therapeutics based?
Monopar Therapeutics's address is: 1000 Skokie Boulevard, Wilmette, IL, United States, 60091 What is Monopar Therapeutics's ISIN number?
Monopar Therapeutics's international securities identification number is: US61023L1089 What is Monopar Therapeutics's CUSIP number?
Monopar Therapeutics's Committee on Uniform Securities Identification Procedures number is: 61023L108
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
9 Best Discount Brokers of 2024 for Low-Cost Trading
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question